CN103536742B - A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof - Google Patents
A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof Download PDFInfo
- Publication number
- CN103536742B CN103536742B CN201310562228.5A CN201310562228A CN103536742B CN 103536742 B CN103536742 B CN 103536742B CN 201310562228 A CN201310562228 A CN 201310562228A CN 103536742 B CN103536742 B CN 103536742B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- rhizoma
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 34
- 201000010099 disease Diseases 0.000 title description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 9
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 92
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- 241000628997 Flos Species 0.000 claims abstract description 17
- 239000009636 Huang Qi Substances 0.000 claims abstract description 17
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 208000005577 Gastroenteritis Diseases 0.000 abstract description 3
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 15
- 239000013641 positive control Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 7
- 230000001741 anti-phlogistic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000023652 chronic gastritis Diseases 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 210000004203 pyloric antrum Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000146 antalgic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010057969 Reflux gastritis Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition for the treatment of chronic enterogastritis, belong to the field of Chinese medicines.In order to overcome prior art deficiency, the invention provides a kind of can the inflammation of relieve chronic gastroenteritis patient, and the Chinese medicine composition of Secondary cases pain and the inflammatory reaction caused by it can be alleviated, obtained by following raw material: Rhizoma et radix veratri (Radix Rhizoma Veratri), Rhizoma Chuanxiong, the Radix Paeoniae Alba, Fructus Aurantii, the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Radix Codonopsis, Herb Gynostemmae Pentaphylli, Radix Et Caulis Acanthopanacis Senticosi, Radix Salviae Miltiorrhizae, Poria, Radix Rehmanniae Preparata, Radix Puerariae, Herba Asari, Herba Menthae, Herba Xanthii, Fructus Ligustri Lucidi, Herba Epimedii, Flos Sophorae, Fructus Corni, the Radix Aucklandiae, Semen Cuscutae, Herba Portulacae, the Radix Astragali, Radix Glycyrrhizae.Pharmacological evaluation and clinical experiment confirm that it has the effect of significant treatment chronic enterogastritis, thus have wide medical science promotional value.
Description
Technical field
The invention belongs to technical field of Chinese medicines, relate to and a kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof.
Background technology
Chronic gastroenteritis is gastric mucosa and intestinal mucosa inflammation.Modal is chronic superficial gastritis and chronic atrophic gastritis.Its main clinical manifestation is loss of appetite, epigastric discomfort and dull pain, belch, pantothenic acid, Nausea and vomiting etc.
Constipation is more common.Feces amount is few, difficult defecation, 1-2 time weekly, occasionally has one time, more than ten sky person, thus often uses cathartic.Sometimes because anal sphincter shrinks, stool is in pencil sample fine strip shape.The symptom diarrhoea of chronic gastroenteritis: every day 1 time or repeatedly.What have only early breaks out repeatedly defecation after meal, and without diarrhoea, can occasionally there be diarrhoea on the 1st more than 20 persons all the other times.Diarrhoea does not occur in night, and can not awaken because of defecate feeling, so do not disturb sleep, also faecal incontinence not occur, with a large amount of white or transparent mucus in the feces of some patient, be mucus even entirely.In the diarrhoea course of disease, often can there is the normal or constipation of the defecation in a period, occur diarrhoea with normal just or the phenomenon that mutually replaces of constipation.
General treatment:
(1) active treatment pars oralis pharyngis focus of infection, the secretions that sputum, nasal mucus etc. do not carried disease germs is swallowed and is caused chronic gastritis into stomach.
(2) keep in high spirits: spirit depressing or hypertonicity and fatigue, easily cause sphincter of pylorus dysfunction, bile reflux and chronic gastritis occurs.
A. due to weakness of spleen and stomach: ferritic is insufficiency of the spleen, or eating and drinking without temperance, irregular diet, make taste injured and weak, shows as gastral cavilty feeling of fullness distending pain, inappetence, abdominal distention after meal, fatigue and weakness, treat with invigorating the spleen and regulating the stomach;
B. spleen-stomach deficiency-cold: insufficiency of the spleen heavier, spleen YANG deficiency, or voracious raw food, damage spleen sun, cause yin-cold excess, show as vague epigastralgia, gain happily temperature by, after meal alleviation of pain, pain of empty stomach is heavy, extremity are chilly, controls with warming the spleen warming the stomach, relieving spasm to stop pain;
C. hyperactive liver-qi attacking the stomach: feelings will is not smooth, depressed rage impairing the liver, hyperactive liver-QI attacking the stomach, mechanism of qi blocks, abnormal ascending-descending of QI, shows as that stomach side of body distending pain, belch are frequent, alleviates after belch or aerofluxus, or feels oppressed with susceptible to lose temper due to restlessness, sighing frequently uncomfortable in chest, cervical region, pharyngeally has the symptoms such as foreign body sensation.Treatment is with depressed liver-energy dispersing and QI regulating and stomach and alleviating pain.
The modal symptom of primary disease is stomach pain and feeling of repletion, especially after the meal exacerbation of symptoms, and pleasant on an empty stomach.Though each food-intake is few, feel satiety and uncomfortable, often with the phenomenon such as belch, acid regurgitation, heartburn, nausea and vomiting, inappetence, dyspepsia.Due to feed less, dyspepsia, malnutrition can be produced, become thin, anemia and weakness.Some patients also with neurological symptom as psychentonia, mood agitation, insomnia, cardiopalmus, forgetful etc., these phenomenons conversely again can the stomach symptom of exacerbates chronic gastritis, forms vicious cycle, makes the state of an illness complicated, not easily cure.
Traditional Chinese medical herbal treatment is clinical conventional method, and its effect is also better, acts on traditional Chinese medical science taste and rules together, the theory of its WEINAIAN, can reach the object of healing.Chinese medicine is of long standing and well established, and it have accumulated abundant clinical practice experience and theory of Chinese medical science in treatment chronic enterogastritis disease, as being instruct with theory of Chinese medical science, then has kidney invigorating and YANG supporting, replenishing QI to invigorate the spleen, methods such as adjusting liver of invigorating blood circulation.
In prior art, chemicals is cured the symptoms, not the disease, and easily damage is gastrointestinal tract mucous, and poisonous side effect of medicine is large, and it is fixed that Chinese medicine then exists uncertain therapeutic efficacy, lacks relative medicine preparation.In order to overcome above-mentioned the deficiencies in the prior art, the object of this invention is to provide and a kind ofly effectively can treat chronic enterogastritis and instant effect, short treating period, Chinese medicine composition that cure rate is high.
For realizing object of the present invention, now according to following technical scheme, Chinese medicine of the present invention is made up of the raw material of following weight: Rhizoma et radix veratri (Radix Rhizoma Veratri) 8-20 part, Rhizoma Chuanxiong 5-15 part, Radix Paeoniae Alba 5-15 part, Fructus Aurantii 3-10 part, Rhizoma Atractylodis Macrocephalae 10-25 part, Radix Angelicae Sinensis 5-15 part, Radix Codonopsis 10-20 part, Herb Gynostemmae Pentaphylli 3-10 part, Radix Et Caulis Acanthopanacis Senticosi 10-20 part, Radix Salviae Miltiorrhizae 5-15 part, Poria 8-20 part, Radix Rehmanniae Preparata 5-12 part, Radix Puerariae 10-20 part, Herba Asari 3-10 part, Herba Menthae 5-15 part, Herba Xanthii 3-10 part, Fructus Ligustri Lucidi 3-10 part, Herba Epimedii 5-12 part, Flos Sophorae 10-15 part, Fructus Corni 10-20 part, Radix Aucklandiae 3-10 part, Semen Cuscutae 5-15 part, Herba Portulacae 5-15 part, Radix Astragali 5-25 part, Radix Glycyrrhizae 10-20 part.
According to the difference of Chinese medicine composition to chronic enterogastritis therapeutic effect, above-mentioned Chinese medicine composition basis is preferably as follows:
(1) Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Chuanxiong 10 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 7 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Radix Angelicae Sinensis 10 parts, Radix Codonopsis 15 parts, Herb Gynostemmae Pentaphylli 7 parts, Radix Et Caulis Acanthopanacis Senticosi 15 parts, Radix Salviae Miltiorrhizae 10 parts, 14 parts, Poria, 9 parts, Radix Rehmanniae Preparata, Radix Puerariae 15 parts, Herba Asari 7 parts, Herba Menthae 10 parts, Herba Xanthii 7 parts, Fructus Ligustri Lucidi 6 parts, Herba Epimedii 8 parts, 13 parts, Flos Sophorae, Fructus Corni 15 parts, the Radix Aucklandiae 7 parts, Semen Cuscutae 10 parts, Herba Portulacae 10 parts, the Radix Astragali 20 parts, 15 parts, Radix Glycyrrhizae.
(2) Rhizoma et radix veratri (Radix Rhizoma Veratri) 8 parts, Rhizoma Chuanxiong 5 parts, the Radix Paeoniae Alba 5 parts, Fructus Aurantii 3 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Radix Angelicae Sinensis 5 parts, Radix Codonopsis 10 parts, Herb Gynostemmae Pentaphylli 3 parts, Radix Et Caulis Acanthopanacis Senticosi 10 parts, Radix Salviae Miltiorrhizae 5 parts, 8 parts, Poria, 5 parts, Radix Rehmanniae Preparata, Radix Puerariae 10 parts, Herba Asari 3 parts, Herba Menthae 5 parts, Herba Xanthii 3 parts, Fructus Ligustri Lucidi 3 parts, Herba Epimedii 5 parts, 10 parts, Flos Sophorae, Fructus Corni 10 parts, the Radix Aucklandiae 3 parts, Semen Cuscutae 5 parts, Herba Portulacae 5 parts, the Radix Astragali 5 parts, 10 parts, Radix Glycyrrhizae.
(3) Rhizoma et radix veratri (Radix Rhizoma Veratri) 20 parts, Rhizoma Chuanxiong 15 parts, the Radix Paeoniae Alba 15 parts, Fructus Aurantii 10 parts, the Rhizoma Atractylodis Macrocephalae 25 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 20 parts, Herb Gynostemmae Pentaphylli 10 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 15 parts, 20 parts, Poria, 12 parts, Radix Rehmanniae Preparata, Radix Puerariae 20 parts, Herba Asari 10 parts, Herba Menthae 15 parts, Herba Xanthii 10 parts, Fructus Ligustri Lucidi 10 parts, Herba Epimedii 12 parts, 15 parts, Flos Sophorae, Fructus Corni 20 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 15 parts, Herba Portulacae 15 parts, the Radix Astragali 25 parts, 20 parts, Radix Glycyrrhizae.
(4) Rhizoma et radix veratri (Radix Rhizoma Veratri) 12 parts, Rhizoma Chuanxiong 12 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 5 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 13 parts, Herb Gynostemmae Pentaphylli 6 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 10 parts, 10 parts, Poria, 8 parts, Radix Rehmanniae Preparata, Radix Puerariae 16 parts, Herba Asari 6 parts, Herba Menthae 10 parts, Herba Xanthii 5 parts, Fructus Ligustri Lucidi 8 parts, Herba Epimedii 7 parts, 11 parts, Flos Sophorae, Fructus Corni 14 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 5 parts, Herba Portulacae 15 parts, the Radix Astragali 15 parts, 17 parts, Radix Glycyrrhizae.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment chronic enterogastritis medicine.Pharmaceutical composition of the present invention, when treating chronic enterogastritis, demonstrates the activity of remarkable anti-inflammatory and antalgic.Test examples 7 of the present invention shows, give positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.Test examples 8 mice of the present invention licks foot response latency time showing, compare with model group, after administration 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control (
p< 0.05) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In a word, Chinese medicine composition of the present invention, in treatment chronic enterogastritis, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improve the compliance of chronic enterogastritis patient, and improve the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and has significant blood circulation promoting and blood stasis dispelling, anti-inflammatory and antalgic isoreactivity, efficiently solve the morbidity root of chronic enterogastritis, it serves the effect for the treatment of both the principal and secondary aspects of a disease to the therapeutic effect of chronic enterogastritis.
3) the present invention is that inventor is on the basis of secret prescription handed down in the family from generation to generation, in conjunction with the summary of clinical experience for many years, obtain through repeatedly testing, therefore this medicine has unique curative effect to the chronic enterogastritis that a variety of causes causes, this medicine compatibility science, curative effect is rapid, the advantage that instant effect, short treating period, cure rate are high, expense is little.
Summary of the invention
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
one) example of formulations part
embodiment 1 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 8 parts, Rhizoma Chuanxiong 5 parts, the Radix Paeoniae Alba 5 parts, Fructus Aurantii 3 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Radix Angelicae Sinensis 5 parts, Radix Codonopsis 10 parts, Herb Gynostemmae Pentaphylli 3 parts, Radix Et Caulis Acanthopanacis Senticosi 10 parts, Radix Salviae Miltiorrhizae 5 parts, 8 parts, Poria, 5 parts, Radix Rehmanniae Preparata, Radix Puerariae 10 parts, Herba Asari 3 parts, Herba Menthae 5 parts, Herba Xanthii 3 parts, Fructus Ligustri Lucidi 3 parts, Herba Epimedii 5 parts, 10 parts, Flos Sophorae, Fructus Corni 10 parts, the Radix Aucklandiae 3 parts, Semen Cuscutae 5 parts, Herba Portulacae 5 parts, the Radix Astragali 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 4 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%, reflux, extract, three times, return time is 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
embodiment 2 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 20 parts, Rhizoma Chuanxiong 15 parts, the Radix Paeoniae Alba 15 parts, Fructus Aurantii 10 parts, the Rhizoma Atractylodis Macrocephalae 25 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 20 parts, Herb Gynostemmae Pentaphylli 10 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 15 parts, 20 parts, Poria, 12 parts, Radix Rehmanniae Preparata, Radix Puerariae 20 parts, Herba Asari 10 parts, Herba Menthae 15 parts, Herba Xanthii 10 parts, Fructus Ligustri Lucidi 10 parts, Herba Epimedii 12 parts, 15 parts, Flos Sophorae, Fructus Corni 20 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 15 parts, Herba Portulacae 15 parts, the Radix Astragali 25 parts, 20 parts, Radix Glycyrrhizae.
Preparation method: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 90%, reflux, extract, three times, return time is 3h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
embodiment 3 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Chuanxiong 10 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 7 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Radix Angelicae Sinensis 10 parts, Radix Codonopsis 15 parts, Herb Gynostemmae Pentaphylli 7 parts, Radix Et Caulis Acanthopanacis Senticosi 15 parts, Radix Salviae Miltiorrhizae 10 parts, 14 parts, Poria, 9 parts, Radix Rehmanniae Preparata, Radix Puerariae 15 parts, Herba Asari 7 parts, Herba Menthae 10 parts, Herba Xanthii 7 parts, Fructus Ligustri Lucidi 6 parts, Herba Epimedii 8 parts, 13 parts, Flos Sophorae, Fructus Corni 15 parts, the Radix Aucklandiae 7 parts, Semen Cuscutae 10 parts, Herba Portulacae 10 parts, the Radix Astragali 20 parts, 15 parts, Radix Glycyrrhizae.
Preparation method: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
embodiment 4 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 8 parts, Rhizoma Chuanxiong 15 parts, the Radix Paeoniae Alba 15 parts, Fructus Aurantii 3 parts, the Rhizoma Atractylodis Macrocephalae 25 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 10 parts, Herb Gynostemmae Pentaphylli 10 parts, Radix Et Caulis Acanthopanacis Senticosi 10 parts, Radix Salviae Miltiorrhizae 10 parts, 16 parts, Poria, 12 parts, Radix Rehmanniae Preparata, Radix Puerariae 10 parts, Herba Asari 3 parts, Herba Menthae 5 parts, Herba Xanthii 10 parts, Fructus Ligustri Lucidi 10 parts, Herba Epimedii 7 parts, 10 parts, Flos Sophorae, Fructus Corni 15 parts, the Radix Aucklandiae 3 parts, Semen Cuscutae 10 parts, Herba Portulacae 10 parts, the Radix Astragali 10 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 5 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 12 parts, Rhizoma Chuanxiong 12 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 5 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 13 parts, Herb Gynostemmae Pentaphylli 6 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 10 parts, 10 parts, Poria, 8 parts, Radix Rehmanniae Preparata, Radix Puerariae 16 parts, Herba Asari 6 parts, Herba Menthae 10 parts, Herba Xanthii 5 parts, Fructus Ligustri Lucidi 8 parts, Herba Epimedii 7 parts, 11 parts, Flos Sophorae, Fructus Corni 14 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 5 parts, Herba Portulacae 15 parts, the Radix Astragali 15 parts, 17 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 4.
embodiment 6 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows:
Rhizoma et radix veratri (Radix Rhizoma Veratri) 14 parts, Rhizoma Chuanxiong 10 parts, the Radix Paeoniae Alba 13 parts, Fructus Aurantii 6 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 20 parts, Herb Gynostemmae Pentaphylli 3 parts, Radix Et Caulis Acanthopanacis Senticosi 16 parts, Radix Salviae Miltiorrhizae 9 parts, 11 parts, Poria, 7 parts, Radix Rehmanniae Preparata, Radix Puerariae 16 parts, Herba Asari 7 parts, Herba Menthae 11 parts, Herba Xanthii 5 parts, Fructus Ligustri Lucidi 10 parts, Herba Epimedii 12 parts, 15 parts, Flos Sophorae, Fructus Corni 16 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 15 parts, Herba Portulacae 12 parts, the Radix Astragali 18 parts, 17 parts, Radix Glycyrrhizae.
Preparation technology is with embodiment 4.
(2) test examples part
the antiinflammatory action of embodiment 7 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, be synthetic be also naturally occurring glucocorticoid, after hydrocortisone enters cell, activate cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.
, experimental technique:
40 KM mices, male and female half and half, body weight 25-30 gram, four groups are divided at random, i.e. dosage group in model control group, compositions high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 50mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in compositions: gavage gives 20 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition presses crude drug gauge;
Compositions low dose group: gavage gives 5 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition presses crude drug gauge.
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03 ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
, experimental result:
Measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 1.
Table 1 each experimental mice ear method of double differences compares
Compare with model control group,
* p< 0.05; Compare with model control group,
* p< 0.01;
Compare with positive controls,
# p< 0.05; Compare with positive controls,
## p< 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
embodiment 8 Chinese medicine composition of the present invention affects mouse hot-plate analgesic
1 mouse hot-plate pain model makes
About body weight 20g female mice is placed on hot plate dolorimeter, screen qualified ♀ mice 90 (to lick metapedes time < 5 s or > 30 s to throw aside, scald for preventing foot, also deadline should be established, be generally 60s), the incubation period of metapedes reaction is added for threshold of pain index with mice, get 72 jennies, be divided into 6 groups, 12/group, i.e. model group, cydiodine, Huanglianshangqing Tablet group, Chinese medicine composition of the present invention (obtaining by Chinese medicine composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, and after successive administration 14d, after measuring last medicine, 60 min, 120 min add the time of foot reaction.
2 Chinese medicine compositions of the present invention are on the impact of licking the foot response latency in mouse hot-plate analgesic experiment
Mice licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (
p< 0.05) and Huanglianshangqing Tablet group (1h,
p< 0.05; 2h,
p< 0.01) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 3.
Table 2 mice lick foot response latency timetable (
)
Note: compare with model group, *
p< 0.05, * *
p< 0.01.
the clinical therapeutic efficacy of embodiment 9 Chinese medicine composition of the present invention
One, case:
For showing the therapeutic effect of Chinese medicine of the present invention to chronic enterogastritis, the present inventor is to 72 routine case clinical observations, and wherein man 34 example, female 38 is routine, 20 ~ 70 years old age.The shortest person of the course of disease 3 months, most elder reaches 2 years, average 0.5 year.
Two, diagnostic criteria:
(1) superficial gastritis
1, asymptomatic or have upper abdominal pain, glutted, belch, decreased food intake etc., occasionally there is upper gastrointestinal hemorrhage;
2, the barium meal examination of X line lacks positive sign;
3, gastric analysis: gastric acid is normal or slightly high;
4, endoscopy is shown in mucosa (reddish tint is main) red and white, and edema, has thick, sticky mucus to adhere to, and can have rotten to the corn and hemorrhage; Mucosa Biopsy is shallow-layer inflammatory cell infiltration, and body of gland is normal;
(2) atrophic gastritis typing standard is as follows:
1, body of stomach gastritis (A type): pathological changes at body of stomach, diffusivity; Gastric acid lacks as or obviously lowers; Serum gastrin raises; Parietal cell antibodies (PCA) etc. are most positive; IFA can be positive, can merge pernicious anemia;
2, gastric antrum gastritis (B type): pathological changes, mainly at gastric antrum, can involve body, stove; Gastric acid is normal or lower slightly; Serum gastrin is normal; BCA, PCA may be positive, can canceration (<4%).Microscopy: can make a definite diagnosis, pathological changes can be confined to body of stomach or gastric antrum portion, also can disperse; Mucosa is greyish white or red and white (Bai Xiangwei master), and pleat attenuates, and mucosa is thinning, and submucosal blood vessel is shown in thoroughly; Sometimes gland nest hypertrophy, local mucous membrane is thickening to be changed in graininess (cross and formed).Mucosa Biopsy is shown in holostrome cell infiltration, and the large portion of body of gland disappears or disappears (gastratrophia) completely, and generation, severe patient had atypical hyperplasia with intestinal gland metaplasia or gland metaplasia.
Three, usage and dosage: during clinical practice, the component in compositions, consumption take the circumstances into consideration increase and decrease according to the body weight of patient, age and symptom.Experimental group uses embodiment 3 gained Chinese medicine capsules, one day twice, and each 20mg/kg takes sooner or later after meal every day half an hour.Matched group takes the intestines and stomach relieving capsule.Two groups was all 1 course for the treatment of with 30 days, evaluated curative effect after 3 courses for the treatment of.Period in a medicine is avoided eating anything raw or cold, pungent thing.
Four, criterion of therapeutical effect:
(1) cure: clinical cardinal symptom and sign disappear, and chronic inflammatory disease is pass on well slightly;
(2) effective: clinical cardinal symptom disappears, and minor symptom disappears substantially, chronic inflammatory disease takes a turn for the better;
(3) effective: cardinal symptom obviously alleviates, and inflammation alleviates to some extent;
(4) invalid; Cardinal symptom is unchanged, does not also worsen.
Five, therapeutic effect:
After taking medicine of the present invention, 26 people cure, and cure rate reaches 72.2%, and 8 people are effective, and total effective rate reaches 94.5%.Matched group cures 25 examples, and effective 5 examples, cure rate is 69.4%, and total effective rate is 83.4%.
Claims (8)
1. treat the Chinese medicine composition of chronic enterogastritis for one kind, it is characterized in that: described Chinese medicine composition is obtained by the raw material of following weight portion: Rhizoma et radix veratri (Radix Rhizoma Veratri) 8-20 part, Rhizoma Chuanxiong 5-15 part, Radix Paeoniae Alba 5-15 part, Fructus Aurantii 3-10 part, Rhizoma Atractylodis Macrocephalae 10-25 part, Radix Angelicae Sinensis 5-15 part, Radix Codonopsis 10-20 part, Herb Gynostemmae Pentaphylli 3-10 part, Radix Et Caulis Acanthopanacis Senticosi 10-20 part, Radix Salviae Miltiorrhizae 5-15 part, Poria 8-20 part, Radix Rehmanniae Preparata 5-12 part, Radix Puerariae 10-20 part, Herba Asari 3-10 part, Herba Menthae 5-15 part, Herba Xanthii 3-10 part, Fructus Ligustri Lucidi 3-10 part, Herba Epimedii 5-12 part, Flos Sophorae 10-15 part, Fructus Corni 10-20 part, Radix Aucklandiae 3-10 part, Semen Cuscutae 5-15 part, Herba Portulacae 5-15 part, Radix Astragali 5-25 part, Radix Glycyrrhizae 10-20 part.
2. the Chinese medicine composition for the treatment of chronic enterogastritis as claimed in claim 1, it is characterized in that: described Chinese medicine composition is obtained by the raw material of following weight portion: Rhizoma et radix veratri (Radix Rhizoma Veratri) 15 parts, Rhizoma Chuanxiong 10 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 7 parts, the Rhizoma Atractylodis Macrocephalae 18 parts, Radix Angelicae Sinensis 10 parts, Radix Codonopsis 15 parts, Herb Gynostemmae Pentaphylli 7 parts, Radix Et Caulis Acanthopanacis Senticosi 15 parts, Radix Salviae Miltiorrhizae 10 parts, 14 parts, Poria, 9 parts, Radix Rehmanniae Preparata, Radix Puerariae 15 parts, Herba Asari 7 parts, Herba Menthae 10 parts, Herba Xanthii 7 parts, Fructus Ligustri Lucidi 6 parts, Herba Epimedii 8 parts, 13 parts, Flos Sophorae, Fructus Corni 15 parts, the Radix Aucklandiae 7 parts, Semen Cuscutae 10 parts, Herba Portulacae 10 parts, the Radix Astragali 20 parts, 15 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of chronic enterogastritis as claimed in claim 1, it is characterized in that, described Chinese medicine composition is obtained by the raw material of following weight portion: Rhizoma et radix veratri (Radix Rhizoma Veratri) 8 parts, Rhizoma Chuanxiong 5 parts, the Radix Paeoniae Alba 5 parts, Fructus Aurantii 3 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Radix Angelicae Sinensis 5 parts, Radix Codonopsis 10 parts, Herb Gynostemmae Pentaphylli 3 parts, Radix Et Caulis Acanthopanacis Senticosi 10 parts, Radix Salviae Miltiorrhizae 5 parts, 8 parts, Poria, 5 parts, Radix Rehmanniae Preparata, Radix Puerariae 10 parts, Herba Asari 3 parts, Herba Menthae 5 parts, Herba Xanthii 3 parts, Fructus Ligustri Lucidi 3 parts, Herba Epimedii 5 parts, 10 parts, Flos Sophorae, Fructus Corni 10 parts, the Radix Aucklandiae 3 parts, Semen Cuscutae 5 parts, Herba Portulacae 5 parts, the Radix Astragali 5 parts, 10 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of chronic enterogastritis as claimed in claim 1, it is characterized in that: described Chinese medicine composition is obtained by the raw material of following weight portion: Rhizoma et radix veratri (Radix Rhizoma Veratri) 20 parts, Rhizoma Chuanxiong 15 parts, the Radix Paeoniae Alba 15 parts, Fructus Aurantii 10 parts, the Rhizoma Atractylodis Macrocephalae 25 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 20 parts, Herb Gynostemmae Pentaphylli 10 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 15 parts, 20 parts, Poria, 12 parts, Radix Rehmanniae Preparata, Radix Puerariae 20 parts, Herba Asari 10 parts, Herba Menthae 15 parts, Herba Xanthii 10 parts, Fructus Ligustri Lucidi 10 parts, Herba Epimedii 12 parts, 15 parts, Flos Sophorae, Fructus Corni 20 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 15 parts, Herba Portulacae 15 parts, the Radix Astragali 25 parts, 20 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition for the treatment of chronic enterogastritis as claimed in claim 1, it is characterized in that: described Chinese medicine composition is obtained by the raw material of following weight portion: Rhizoma et radix veratri (Radix Rhizoma Veratri) 12 parts, Rhizoma Chuanxiong 12 parts, the Radix Paeoniae Alba 10 parts, Fructus Aurantii 5 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, Radix Angelicae Sinensis 15 parts, Radix Codonopsis 13 parts, Herb Gynostemmae Pentaphylli 6 parts, Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Salviae Miltiorrhizae 10 parts, 10 parts, Poria, 8 parts, Radix Rehmanniae Preparata, Radix Puerariae 16 parts, Herba Asari 6 parts, Herba Menthae 10 parts, Herba Xanthii 5 parts, Fructus Ligustri Lucidi 8 parts, Herba Epimedii 7 parts, 11 parts, Flos Sophorae, Fructus Corni 14 parts, the Radix Aucklandiae 10 parts, Semen Cuscutae 5 parts, Herba Portulacae 15 parts, the Radix Astragali 15 parts, 17 parts, Radix Glycyrrhizae.
6. the Chinese medicine composition of the treatment chronic enterogastritis as described in as arbitrary in claim 1-5, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
7. according to the preparation method of the Chinese medicine composition of the arbitrary described treatment chronic enterogastritis of claim 1-5, it is characterized in that: described preparation method comprises the steps: that getting the above-mentioned Chinese crude drug of recipe quantity is broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying.
8. the Chinese medicine composition of the arbitrary described treatment chronic enterogastritis of claim 1-5 is preparing the purposes in chronic enterogastritis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562228.5A CN103536742B (en) | 2013-11-13 | 2013-11-13 | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562228.5A CN103536742B (en) | 2013-11-13 | 2013-11-13 | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103536742A CN103536742A (en) | 2014-01-29 |
| CN103536742B true CN103536742B (en) | 2015-09-16 |
Family
ID=49960856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310562228.5A Active CN103536742B (en) | 2013-11-13 | 2013-11-13 | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103536742B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689046A (en) * | 2015-04-01 | 2015-06-10 | 青岛云天生物技术有限公司 | Traditional Chinese medicine composition for treating bile reflux gastritis and application thereof |
| CN104906322A (en) * | 2015-07-12 | 2015-09-16 | 佛山市朗达信息科技有限公司 | Medicine composition for treating gastritis |
| CN104958502A (en) * | 2015-07-12 | 2015-10-07 | 佛山市朗达信息科技有限公司 | Traditional Chinese medicine composition for treating gastropathy and preparation method thereof |
| CN104922387A (en) * | 2015-07-12 | 2015-09-23 | 佛山市朗达信息科技有限公司 | Medicine composition for treating gastric ulcer |
| CN105031504A (en) * | 2015-09-22 | 2015-11-11 | 董地 | Preparation for treating chronic enterogastritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757281A (en) * | 2008-12-24 | 2010-06-30 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof |
| CN101785845A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method for intestinal flatulence treatment |
| CN102430092A (en) * | 2011-12-13 | 2012-05-02 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composite for treating stomach cold and stomachache |
-
2013
- 2013-11-13 CN CN201310562228.5A patent/CN103536742B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757281A (en) * | 2008-12-24 | 2010-06-30 | 天津中新药业集团股份有限公司乐仁堂制药厂 | Traditional Chinese medicine composition for treating gastrointestinal disease and preparation method thereof |
| CN101785845A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method for intestinal flatulence treatment |
| CN102430092A (en) * | 2011-12-13 | 2012-05-02 | 荣成市科学技术情报研究所 | Traditional Chinese medicine composite for treating stomach cold and stomachache |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103536742A (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
| CN100364594C (en) | Medicine for treating chronic superficial gastritis and peptic ulcer diseases | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN102973895A (en) | Traditional Chinese medicine combination for treating nervous vomiting | |
| CN101036717B (en) | Orally taken type Chinese traditional medicine combination for curing irritable bowel syndrome | |
| CN102641463A (en) | Traditional Chinese medicine composition for treating diarrhea-predominant irritable bowel syndrome | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN101342360B (en) | Chinese medicinal composition for treating esophagus cancer | |
| CN104721256A (en) | Anwei Yang extract as well as preparation method and medical application thereof | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN103191331A (en) | Traditional Chinese medicine composition for treating bronchial asthma in remission stage | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103877384B (en) | A kind of Chinese medicine preparation and preparation method who treats the carcinoma of the rectum | |
| CN104491816A (en) | Application of traditional Chinese medicinal composition in preparation of medicine for treating chronic gastroenteritis | |
| CN103520354A (en) | Traditional Chinese medicine for treatment of blood-insufficiency type mammary gland hyperplasia and preparation method thereof | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| Li et al. | Application of Invigorating Qi and Moistening Intestines Method in Qi Deficiency Constipation | |
| CN101618187A (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN105233180A (en) | Drug for treating internal hemorrhoid due to damp-heat pouring downward syndrome | |
| CN102836343B (en) | Medicine for colon nursing and colitis treatment | |
| CN105477336A (en) | Spleen-strengthening stomach-harmonizing ointment resistant to side effects of chemotherapy | |
| CN104189646A (en) | Traditional Chinese medicine for treating damp-heat type 2 diabetes mellitus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Dong Yuanli Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: DONG YUANLI |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170428 Address after: 17 groups of Yang Zhen Dong Qinghe Village Qidong City Yin 226200 Jiangsu city of Nantong Province Patentee after: Qidong Qing Han agricultural cooperatives Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee before: Cui Hefang |